Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Storiesrttnews·8 hours agoAKTX+18.76%AIM+3.36%
U.S. stock market intraday update: AIM rises 12.10% with increased volume and unusual activity, no major positive drivers, intensified capital speculationPrice Alert·Aug 17 at 12:32 PMAIM+3.36%
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ ArticleUnusual Whales·Aug 12 at 07:46 AMAIM+3.36%
AIM: Earnings rebounded on Bozzetto sale, with strong cash growth and ongoing cost disciplineQuartr·Aug 11 at 05:13 AMAIM+3.36%
AIM ImmunoTech | 8-K: FY2026 Q2 Revenue Meets Estimate at USD 0Earnings Watch·Aug 10 at 07:42 AMAIM+3.36%
Aim Immunotech’s Aggressive Equity Issuance Raises $10.4M but Poses Major Dilution Risk for ShareholdersTip Ranks·Aug 10 at 01:01 AMAIM+3.36%
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer | AIM Stock NewsStockTitan·Aug 9 at 11:36 PMAIM+3.36%
AIM ImmunoTech signs manufacturing pact with Sterling Pharma, cost seen at $1.5 millionPUBT·Aug 6 at 05:24 PMAIM+3.36%
AIM ImmunoTech completes last dosing in Phase 2 DURIPANC trial of Ampligen plus AstraZeneca Imfinzi in metastatic pancreatic cancerPUBT·Aug 3 at 07:33 AMAIM+3.36%AZN-1.11%
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program | AIM Stock NewsStockTitan·Jul 7 at 12:03 AMAIM+3.36%AZN-1.11%
AIM ImmunoTech completes Phase 2 DURIPANC trial enrollment for Ampligen-Imfinzi in metastatic pancreatic cancerPUBT·Jun 24 at 07:29 AMAZN-1.11%AIM+3.36%
